The Company expects the cash, cash equivalents and investments on hand at March 31, 2023 and expected net cash inflows from product sales will enable it to fund current and planned operations into the second half of 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EYPT:
- EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
- EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
- Biotech Alert: Searches spiking for these stocks today
- EyePoint initiated with Outperform, $33 price target at Baird
- EyePoint initiated with an Outperform at Baird